Lyell Immunopharma is a biotechnology business based in the US. Lyell Immunopharma shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.92 – a decrease of 16.67% over the previous week. Lyell Immunopharma employs 224 staff and has a trailing 12-month revenue of around $63,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.92 |
|---|---|
| 52-week range | $0.85 - $3.26 |
| 50-day moving average | $1.20 |
| 200-day moving average | $1.83 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.79 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.9166 from 2024-11-21
| 1 week (2024-11-15) | -16.67% |
|---|---|
| 1 month (2024-10-23) | -20.30% |
| 3 months (2024-08-22) | -36.79% |
| 6 months (2024-05-22) | -66.79% |
| 1 year (2023-11-22) | -47.02% |
|---|---|
| 2 years (2022-11-22) | -78.58% |
| 3 years (2021-11-22) | 9.8 |
| 5 years (2019-11-19) | N/A |
| Revenue TTM | $63,000 |
|---|---|
| Gross profit TTM | $84.7 million |
| Return on assets TTM | -19.12% |
| Return on equity TTM | -33.22% |
| Profit margin | 0% |
| Book value | $2.07 |
| Market Capitalization | $255.9 million |
TTM: trailing 12 months
We're not expecting Lyell Immunopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Lyell Immunopharma's shares have ranged in value from as little as $0.85 up to $3.2556. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lyell Immunopharma's is -0.483. This would suggest that Lyell Immunopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lyell Immunopharma has bucked the trend.
To put Lyell Immunopharma's beta into context you can compare it against those of similar companies.
Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.